Evidence map›Paper›PMID 41273757›Full record

ArticleCancer communications (London, England)2025

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01).

Chuanhua Zhao, Jun Zhao, Yigui Chen, Bo Liu, Yangfeng Du, Chenglin Li, Jingdong Zhang, Mudan Yang, Ying Liu, Yuxian Bai and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Unmasking hidden trends: subsite-specific mortality patterns in colorectal and anal cancers in Spain, 1999-2023.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chuanhua ZhaoSenior Department of Oncology, Chinese PLA General Hospital, Beijing, P. R. China.
Jun ZhaoDepartment of Oncology, Changzhi People's Hospital, Changzhi, Shanxi, P. R. China.
Yigui ChenDepartment of Medicine, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, P. R. China.
Bo LiuDepartment of Medical Oncology, Cancer Hospital of Shandong First Medical University, Jinan, Shandong, P. R. China.
Yangfeng DuDepartment of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, P. R. China.
Chenglin LiDepartment of Clinical Pharmacology, Linyi People's Hospital, Linyi, Shandong, P. R. China.
Jingdong ZhangDepartment of Gastroenterology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, P. R. China.
Mudan YangDepartment of Special Medical Services, Shanxi Province Cancer Hospital, Taiyuan, Shanxi, P. R. China.
Ying LiuDepartment of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
Yuxian BaiDepartment of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Suyi LiDepartment of Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, P. R. China.
Ruixing ZhangDepartment of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Fangling NingDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, P. R. China.
Yanping LiuClinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China.
Kai ZouClinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China.
Qi ZhangClinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China.
Yijiao XieClinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China.
Yuping AnClinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China.
Jianming XuSenior Department of Oncology, Chinese PLA General Hospital, Beijing, P. R. China.ORCID https://orcid.org/0000-0003-4467-6021

Funding

Shanghai JMT-Bio Technology Co., Ltd
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41273757
PMCPMC12728473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.